Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + cisplatin + sintilimab
- Development stage
- Unknown
- Lead developer
- Suzhou Innovent Biologics
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A combination therapy consisting of nab-paclitaxel (albumin-bound paclitaxel), cisplatin, and sintilimab. This regimen combines two chemotherapeutic agents with an immune checkpoint inhibitor. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel that inhibits cell division by stabilizing microtubules. Cisplatin is a platinum-based chemotherapy that causes DNA crosslinking, leading to apoptosis in cancer cells. Sintilimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell immune responses against tumor cells. This combination approach aims to leverage both cytotoxic effects of chemotherapy and immune system activation to treat advanced solid tumors.
- Other names
- nab-paclitaxel + cisplatin + sintilimabAlbumin-Bound Paclitaxel + cisplatin + sintilimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on nab-paclitaxel + cisplatin + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + cisplatin + sintilimab.